AnaptysBio (NASDAQ:ANAB) Lowered to Hold at Stifel Nicolaus

AnaptysBio (NASDAQ:ANAB) was downgraded by equities research analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, June 21st, Marketbeat Ratings reports. They presently have a $74.00 price target on the biotechnology company’s stock, down from their prior price target of $124.00. Stifel Nicolaus’ price target would indicate a potential upside of 35.68% from the stock’s current price.

Other analysts have also issued research reports about the stock. Credit Suisse Group cut their target price on shares of from GBX 145 ($1.89) to GBX 105 ($1.37) and set a “neutral” rating on the stock in a research report on Friday, June 21st. Zacks Investment Research lowered shares of GENEL ENERGY PL/ADR from a “buy” rating to a “hold” rating in a research report on Tuesday, May 7th. Cantor Fitzgerald raised their target price on shares of Horizon Therapeutics from $26.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Wedbush reaffirmed an “outperform” rating on shares of AnaptysBio in a research note on Friday, March 1st. Finally, Guggenheim set a $27.00 price target on shares of Cabot Oil & Gas and gave the company a “hold” rating in a research note on Friday, February 22nd. One investment analyst has rated the stock with a sell rating, four have given a hold rating and eight have assigned a buy rating to the stock. AnaptysBio has a consensus rating of “Buy” and an average price target of $111.25.

Shares of NASDAQ ANAB traded up $0.43 during trading hours on Friday, hitting $54.54. 188,365 shares of the stock were exchanged, compared to its average volume of 381,793. The firm has a market cap of $1.47 billion, a P/E ratio of -21.82 and a beta of 1.38. The firm has a fifty day moving average of $65.13. AnaptysBio has a 1-year low of $52.71 and a 1-year high of $110.00.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.83) by $0.01. On average, analysts anticipate that AnaptysBio will post -3.76 EPS for the current year.

In other news, CEO Hamza Suria sold 22,428 shares of AnaptysBio stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $73.76, for a total transaction of $1,654,289.28. Following the completion of the transaction, the chief executive officer now directly owns 31,524 shares in the company, valued at $2,325,210.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Marco Londei sold 10,060 shares of AnaptysBio stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $73.06, for a total transaction of $734,983.60. Following the transaction, the insider now owns 32,437 shares of the company’s stock, valued at $2,369,847.22. The disclosure for this sale can be found here. Company insiders own 14.00% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of ANAB. Diag Capital Management LP purchased a new position in AnaptysBio during the fourth quarter worth about $95,000. Amundi Pioneer Asset Management Inc. purchased a new position in AnaptysBio during the first quarter worth about $110,000. SG Americas Securities LLC purchased a new position in AnaptysBio during the fourth quarter worth about $126,000. Bank of America Corp DE boosted its holdings in AnaptysBio by 141.2% during the fourth quarter. Bank of America Corp DE now owns 4,397 shares of the biotechnology company’s stock worth $281,000 after purchasing an additional 15,067 shares during the last quarter. Finally, Janney Montgomery Scott LLC purchased a new position in AnaptysBio during the first quarter worth about $290,000.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.

See Also: What is the Bid-Ask Spread?

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.